EU, AstraZeneca Corona 19 Vaccine Official Approval (Comprehensive 2 Report)

EU, AstraZeneca Corona 19 Vaccine Official Approval (Comprehensive 2 Report)

by

Third COVID-19 vaccine available in 27 member states

[로이터=연합뉴스 자료사진]

[로이터=연합뉴스 자료사진]

(Brussels = Yonhap News) Correspondent Kim Jong-un = On the 29th (local time), the executive committee, a member of the European Union (EU) administration, announced a conditional sale of a novel coronavirus infectious disease (Corona 19) vaccine jointly developed by a multinational pharmaceutical company AstraZeneca and Oxford University in the UK. Officially approved.

Executive Chairman Ursula Ponderrayen said on Twitter that day, “I look forward to the company delivering 400 million batches as agreed. We are committed to securing vaccines for Europeans, our neighbors and our partners around the world. “We will continue to do everything we can.”

The EU decision came a few hours after the European Medicines Agency (EMA) recommended conditional marketing approval for the vaccine to targets 18 years of age and older.

This is the third COVID-19 vaccine that the EU has approved for conditional use following a vaccine developed by US pharmaceutical company Pfizer-German Bioentech and US Modena.

The EU has signed a contract to purchase 400 million doses of vaccine with AstraZeneca on behalf of the member states.

EMA said that the AstraZeneca vaccine was found to be safe and effective in preventing COVID-19 in people over the age of 18 when the results of clinical trials conducted in the UK, Brazil and South Africa were combined.

The EMA added that most of the participants in the vaccine trial were between 18 and 55 years of age, and there are still not enough results to provide a measure of how well the vaccine will work in the ages over 55.

EMA, however, expects to have a protective effect based on experience with other vaccines, taking into account the immune response seen at that age group.

Earlier, some observations have been made that the EMA may recommend vaccination only to those under the age of 65.

[로이터=연합뉴스 자료사진]

[로이터=연합뉴스 자료사진]

The vaccination committee under the Robert Koch Institute (RKI), a German disease control agency, said that the previous day, the AstraZeneca-Oxford Vaccine did not have sufficient clinical trials for people over 65 years old. Said.

In addition, EMA added that the vaccine should be administered in the first and second doses, and the vaccination interval should be 4 to 12 weeks.

The EU’s conditional marketing approval is a procedure to quickly respond to emergencies that threaten public health such as COVID-19, allowing pharmaceuticals to be sold for one year in 27 member states and can be renewed annually.

The EU previously approved the conditional sale of the Modena vaccine in the EU earlier this month following the COVID-19 vaccine jointly developed by US pharmaceutical company Pfizer and Bioentech on the 21st of last month according to EMA’s recommendation.

Accordingly, in EU member states, Pfizer-Bioentech vaccination began on the 27th of last month.

The AstraZeneca vaccine was approved for emergency use in India, Argentina, and Mexico starting in the UK on the 30th of last month.

EMA has said the vaccine has been effective at around 60% in clinical trials, Reuters reported.

However, even if the vaccine is officially approved, the EU must resolve the issues surrounding the initial supply with the pharmaceutical company.

When AstraZeneca announced on the 22nd that the initial supply to Europe would decrease due to a disruption in the production of the Corona 19 vaccine, the EU demanded that the UK-produced vaccine be returned to the EU, causing friction between the two sides.

[email protected]


Unauthorized reproduction-redistribution prohibited>
2021/01/30 04:42 sent

Source